Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications

Overview

Funding for research projects developing personalised approaches to reduce risks from adverse drug reactions (ADRs) caused by multiple medications, targeting healthcare professionals, systems, and patients. Focuses on integrating pharmacogenomics, biomarkers, and technology into clinical decision-making to improve medication safety and cost-effectiveness.

Who Can Apply

Eligible applicants include legal entities from EU Member States, Horizon Europe-associated countries, and the United States. Consortia involving research institutions, healthcare providers, SMEs, startups, and public bodies are encouraged, particularly those with expertise in pharmacogenomics, clinical studies, and digital health technologies.

Funding Details

• Maximum funding per project: €11,000,000
• Funding type: Grant
• Total budget: Not specified
• Co-funding: Not explicitly stated (assumed 100% funding for eligible costs under Horizon Europe rules)

What Is Funded

• Development of personalised medicine strategies (e.g., biomarker-driven treatments, pharmacogenomics) to reduce ADRs from multiple medications (three or more drugs).
• Integration of technology (e.g., AI, electronic health records, clinical decision support systems) to prevent ADRs and optimise medication use.
• Clinical studies to validate biomarkers, drug interactions, and deprescribing strategies, including sex-specific and population-wide differences.
• Cost-effectiveness analyses of pharmacogenomic and biomarker-guided treatments.
• Ethical, regulatory, and implementation frameworks for integrating personalised approaches into healthcare.
• Alignment with EU initiatives (e.g., European Partnership for Personalised Medicine, Transforming Health and Care Systems).

Technology / Maturity Requirements

• Projects must include clinical studies, with a focus on generating robust evidence for regulatory and clinical adoption.
• Use of advanced technologies (e.g., in-vitro/in-silico models, imaging biomarkers, AI) to stratify patients and predict ADRs.
• Proposals should address TRL 4–7 (validation in lab to demonstration in operational environment), though no explicit TRL range is mandated.

Key Dates

• Open date: 2027-02-09
• Deadline: 2027-04-12T22:00:00Z

Application Process (High-Level)

• Single-stage submission: Proposals are evaluated in one round.
• Portal: Funding & Tenders Portal (EC submission system).
• Required annex: Clinical studies template (strongly encouraged for proposals involving clinical research).

Post-Award Obligations

• Data sharing with stakeholders (e.g., European Medicines Agency) to support guideline revisions.
• Dissemination of results to healthcare providers, patients, and policymakers.
• Compliance with Horizon Europe reporting requirements, including financial and scientific progress updates.
• Potential restrictions on ownership transfers or exclusive licensing of results for up to 4 years post-project.

Geographic Scope & Language

• Eligible countries: EU Member States, Horizon Europe-associated countries, and the United States.
• Language: English.

Notes

• Projects must avoid overlap with existing EU-funded initiatives (e.g., European Partnership for Personalised Medicine).
• Participation of SMEs and startups is encouraged to enhance innovation and commercialisation potential.
• Proposals must address sex differences in drug reactions and consider diverse populations.
• Use of Copernicus/Galileo data is mandatory if satellite-based services are employed.